Suppr超能文献

阿片类药物药物遗传学评价及疼痛管理注意事项。

Review of Opioid Pharmacogenetics and Considerations for Pain Management.

机构信息

The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Pharmacy Department, The Mount Sinai Hospital, New York, New York.

出版信息

Pharmacotherapy. 2017 Sep;37(9):1105-1121. doi: 10.1002/phar.1986. Epub 2017 Sep 6.

Abstract

Opioid analgesics are the standards of care for the treatment of moderate to severe nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties mainly emanate from stimulation of the μ receptors, which are encoded by the OPRM1 gene. Hepatic metabolism represents the major route of elimination, which, for some opioids, namely codeine and tramadol, is necessary for their bioactivation into more potent analgesics. The highly polymorphic nature of the genes coding for phase I and phase II enzymes (pharmacokinetics genes) that are involved in the metabolism and bioactivation of opioids suggests a potential interindividual variation in their disposition and, most likely, response. In fact, such an association has been substantiated in several pharmacokinetic studies described in this review, in which drug exposure and/or metabolism differed significantly based on the presence of polymorphisms in these pharmacokinetics genes. Furthermore, in some studies, the observed variability in drug exposure translated into differences in the incidence of opioid-related adverse effects, particularly nausea, vomiting, constipation, and respiratory depression. Although the influence of polymorphisms in pharmacokinetics genes, as well as pharmacodynamics genes (OPRM1 and COMT) on response to opioids has been a subject of intense research, the results have been somehow conflicting, with some evidence insinuating for a potential role for OPRM1. The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations to individualize treatment with tramadol and codeine. However, implementation guidelines for other opioids, which are more commonly used in real-world settings for pain management, are currently lacking. Hence, further studies are warranted to bridge this gap in our knowledge base and ultimately ascertain the role of pharmacogenetic markers as predictors of response to opioid analgesics.

摘要

阿片类镇痛药是治疗中重度伤害性疼痛的标准治疗方法,特别是在癌症和手术治疗中。它们的镇痛作用主要源于对 μ 受体的刺激,而 μ 受体由 OPRM1 基因编码。肝脏代谢是消除的主要途径,对于某些阿片类药物(如可待因和曲马多),这种代谢是将其生物转化为更有效的镇痛药所必需的。编码参与阿片类药物代谢和生物转化的 I 相和 II 相酶(药代动力学基因)的基因高度多态性,表明它们在处置和(很可能)反应方面存在个体间差异。事实上,在本综述中描述的几项药代动力学研究中已经证实了这种关联,其中药物暴露和/或代谢根据这些药代动力学基因的多态性存在显著差异。此外,在一些研究中,观察到的药物暴露差异转化为阿片类相关不良反应(特别是恶心、呕吐、便秘和呼吸抑制)的发生率差异。尽管药代动力学基因(如 CYP2D6)和药效动力学基因(OPRM1 和 COMT)的多态性对阿片类药物反应的影响一直是研究的热点,但结果有些相互矛盾,有些证据暗示 OPRM1 可能起作用。临床药物遗传学实施联盟指南提供了基于 CYP2D6 的治疗建议,以个体化治疗曲马多和可待因。然而,目前缺乏其他在现实世界疼痛管理中更常用的阿片类药物的实施指南。因此,需要进一步的研究来填补我们知识库中的这一空白,并最终确定药物遗传学标志物作为预测阿片类镇痛药反应的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验